For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- FJPWA Calls For Resumption of Ryukaikon
February 7, 2011
- Takeda, MSD Call For Precautions on Similar Drug Names
February 7, 2011
- Meiji Seika, Fresenius Kabi Ally to Develop Anticancer Generics Business in Japan
February 7, 2011
- NBI's Mirapex Recommended for Approval
February 7, 2011
- Mochida Aims at Sales of ¥10 Bil. with Generics
February 7, 2011
- Making Whole of Japan Large Pharmaceutical Company: Prof. Nakamura
February 7, 2011
- Nichi-Iko to Raise ¥20 Bil. through Public Stock Offerings
February 7, 2011
- Pfizer Aims for Approval of 7 Products Each Year: President Umeda
February 7, 2011
- Gov't Rejects Court-Proposed Compromise in Iressa Lawsuits
February 7, 2011
- Torii Starts PIII Trial of Sublingual Desensitization Therapy for Cedar Pollinosis
February 7, 2011
- Dr Teshirogi Calls on Doctors to Cooperate to Obtain More Financial Resources for Healthcare
February 7, 2011
- MTPC Applies for MP-424 in Japan
February 7, 2011
- Takeda Begins PIII Trial of AMG 386 in Japan
February 7, 2011
- MTPC Shipped 4 Injectables without Conducting Necessary Quality Tests
February 7, 2011
- Novartis Applies for Canakinumab for CAPS
February 7, 2011
- Insight Obtained into Mechanism of Nerve Cell Protection Following Cerebral Infarction
February 7, 2011
- Top-4 Wholesalers Report Slow Price Settlement, Difficulty in Reducing Yakkasa
February 7, 2011
- Eisai Won't Seek Regulatory Approval for Eritoran in March
February 7, 2011
- Peretinoin Reduces Risk of HCC Recurrence or Death
February 7, 2011
- JACDS Calls on Its Members to Refrain from Offering Points for Dispensing Services
February 7, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…